Spots Global Cancer Trial Database for Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Official Title: Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma
Study ID: NCT02011594
Study Description
Brief Summary: There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.
Detailed Description: We design this clinical trial to confirm the efficacy of maintenance treatment of nimotuzumab after initial treatment.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Qiong Zhao, Hangzhou, Zhejiang, China
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Contact Details
Name: Qiong Zhao, PhD
Affiliation: First Affiliated Hospital,Zhejiang University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
